Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, Guggenheim Analyst Says

Merck & Co., Inc. (NYSE:MRK) had its target price upped by research analysts at Guggenheim from $140.00 to $145.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective points to a potential upside of 17.20% from the stock’s current price.

A number of other equities research analysts have also recently commented on MRK. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Sunday. Bank of America increased their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Cantor Fitzgerald restated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. JPMorgan Chase & Co. boosted their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. Finally, Scotiabank upped their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research note on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $123.72 on Monday. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $130.29. The stock has a market cap of $305.56 billion, a PE ratio of 34.85, a PEG ratio of 2.65 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm’s 50 day moving average price is $118.83 and its two-hundred day moving average price is $116.36.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current year.

Institutional Trading of Merck & Co., Inc.

Several hedge funds have recently added to or reduced their stakes in the business. Somerset Trust Co increased its holdings in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after acquiring an additional 81 shares in the last quarter. Stonebridge Financial Group LLC raised its position in shares of Merck & Co., Inc. by 0.9% during the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after purchasing an additional 81 shares during the period. Lederer & Associates Investment Counsel CA raised its position in shares of Merck & Co., Inc. by 0.9% during the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock worth $1,234,000 after purchasing an additional 84 shares during the period. Pine Haven Investment Counsel Inc lifted its holdings in shares of Merck & Co., Inc. by 0.6% during the 2nd quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company’s stock valued at $1,834,000 after purchasing an additional 86 shares in the last quarter. Finally, Chesapeake Wealth Management lifted its holdings in shares of Merck & Co., Inc. by 0.6% during the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after purchasing an additional 87 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.